Assembly Biosciences (ASMB) Total Non-Current Liabilities (2014 - 2018)
Assembly Biosciences (ASMB) posted quarterly Total Non-Current Liabilities of $38.9 million for Q4 2018, down 8.84% year-over-year from $42.7 million in Q4 2017, and little changed quarter-over-quarter from $38.9 million in Q3 2018.
Assembly Biosciences (ASMB) Total Non-Current Liabilities (2014 - 2018) Analysis & Trends
Assembly Biosciences' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $38.9 million for Q4 2018.
- In Q4 2018, Total Non-Current Liabilities fell 8.84% year-over-year to $38.9 million; the TTM figure through Dec 2018 stood at $38.9 million (down 8.84% YoY), while the FY2018 annual figure was $38.9 million, down 8.84% from the prior year.
- Total Non-Current Liabilities for Q4 2018 stood at $38.9 million, roughly flat from $38.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $55.4 million in Q1 2017, with the low at $11.1 million in Q4 2016.
- The 5-year median for Total Non-Current Liabilities is $25.3 million (2014), against an average of $28.6 million.
- The sharpest annual moves came in 2017 and 2018: Total Non-Current Liabilities soared 377.93% in 2017, then dropped 26.49% in 2018.
- Assembly Biosciences' Total Non-Current Liabilities stood at $11.6 million in 2014, then changed by 0.0% to $11.6 million in 2015, then slipped by 4.14% to $11.1 million in 2016, then jumped by 283.93% to $42.7 million in 2017, then dropped by 8.84% to $38.9 million in 2018.
- Business Quant data shows ASMB's Total Non-Current Liabilities at $38.9 million in Q4 2018, $38.9 million in Q3 2018, and $40.2 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 38.92 Mn |
| Sep 30, 2018 | 38.93 Mn |
| Jun 30, 2018 | 40.19 Mn |
| Mar 31, 2018 | 41.46 Mn |
| Dec 31, 2017 | 42.69 Mn |
| Sep 30, 2017 | 52.96 Mn |
| Jun 30, 2017 | 54.25 Mn |
| Mar 31, 2017 | 55.44 Mn |
| Dec 31, 2016 | 11.12 Mn |
| Sep 30, 2016 | 11.60 Mn |
| Jun 30, 2016 | 11.60 Mn |
| Mar 31, 2016 | 11.60 Mn |
| Dec 31, 2015 | 11.60 Mn |
| Sep 30, 2015 | 11.60 Mn |
| Jun 30, 2015 | 11.60 Mn |
| Dec 31, 2014 | 11.60 Mn |